‘Breakthrough’ Alzheimer’s drugs unlikely to benefit patients, report suggests

Influential analysis has concluded that "breakthrough" Alzheimer’s drugs, heralded as a significant advancement in dementia treatment, are unlikely to provide meaningful benefit to patients. A comprehensive report authored by UK researchers, specifically the Cochrane Collaboration, suggests that the impact of these amyloid-targeting therapies falls "well below" the threshold required to make a discernible difference in the lives of individuals living with dementia. This critical assessment, however, has ignited a fervent debate within the scientific community, drawing sharp criticism from equally esteemed experts who deem the report’s methodology and conclusions fundamentally flawed. The current reality for patients in the UK is stark: the National Health Service (NHS) does not fund these treatments, and a private 18-month course carries a prohibitive price tag of approximately £90,000, placing them beyond the financial reach of the vast majority. This raises crucial questions about their actual value, even for those who could afford them.

These new class of drugs operate by targeting beta-amyloid, a sticky protein that accumulates in the spaces between brain cells, forming plaques characteristic of Alzheimer’s disease. The approach involves using engineered antibodies, akin to the body’s natural defence mechanisms against viruses and bacteria, designed to identify and clear these amyloid deposits from the brain. While this strategy had previously yielded disappointing results for years, recent clinical trials of two specific drugs, donanemab and lecanemab, demonstrated a statistically significant slowing of cognitive decline. This represented a landmark achievement, marking the first instance where a pharmaceutical intervention showed the ability to decelerate the neurodegenerative process in Alzheimer’s disease.

The Cochrane Collaboration, renowned for its rigorous and independent analysis of medical evidence, meticulously reviewed 17 studies encompassing a total of 20,342 volunteers, all focused on drugs designed to remove amyloid from the brain. Their overarching conclusion is that while these therapies do indeed slow the progression of Alzheimer’s disease, the rate of deceleration is insufficient to translate into a clinically meaningful improvement for patients. Compounding these concerns, the report highlights that these medications are associated with potential risks, including brain swelling and bleeding. Furthermore, their administration requires frequent intravenous infusions, typically every two to four weeks, and their high cost exacerbates issues of accessibility and affordability.

Professor Edo Richard, a professor of neurology at Radboud University Medical Centre in the Netherlands and one of the report’s authors, shared his perspective based on his direct clinical experience with dementia patients. When asked about his message to his patients, he stated, "I would tell them, I think you will probably not benefit from these drugs and they’re burdensome for you and your family. I think it’s extremely important that we’re honest to our patients about what they can expect, I’m always wary to avoid giving people false hope." Professor Richard emphasized the need to explore alternative therapeutic avenues for Alzheimer’s disease, suggesting that approaches focusing on inflammation within the brain, for example, now warrant greater attention and research investment.

The findings of the Cochrane report have found support among long-standing critics of amyloid-targeting therapies. Professor Robert Howard, based at University College London (UCL), described the situation as "unfortunate and unfair" to families impacted by dementia. He argued that these drugs have been subject to a level of hype not substantiated by robust scientific evidence, which has consequently fostered unrealistic expectations and potentially led to false hope.

However, the methodology employed in the Cochrane analysis has become a focal point of intense disagreement. The research team maintains that their review is valid because all the drugs examined share the common mechanism of removing amyloid from the brain, thus providing insights into the efficacy of this overall strategy. Conversely, a significant contingent of other experts contends that the distinct mechanisms of action and the varying stages of development of individual drugs make it inappropriate to group them together. They argue that lumping older, experimental drugs with newer, proven-effective antibodies dilutes the nuances of the evidence and leads to an inaccurate overall assessment.

Professor Bart De Strooper, from the UK Dementia Research Institute at UCL, was particularly critical, stating that the review "does not clarify the evidence, it blurs it" and that "the flaw in this review is fundamental." He elaborated, "Many early programmes failed, but newer antibodies have delivered modest yet real clinical benefit." This sentiment was echoed by Dr. Richard Oakley, from the Alzheimer’s Society, who urged for a more nuanced interpretation of the review, cautioning against a broad-brush dismissal of "decades of pioneering scientific study."

The current landscape for accessing these drugs in the UK remains challenging. Private payment is the sole route, rendering them inaccessible to most individuals. The National Institute for Health and Care Excellence (NICE), the body responsible for determining which drugs the NHS will fund, has previously rejected these therapies. However, NICE is currently undertaking a review of the latest evidence, a move influenced in part by the recognition of the significant burden placed upon unpaid carers, suggesting a potential shift in their evaluation process. The ongoing debate underscores the complex interplay between scientific discovery, clinical utility, economic realities, and the profound human impact of Alzheimer’s disease.